Gliosarcoma - Pipeline Review, H1 2020

May 2020 | 350 pages | ID: G4F98205B88EN
Global Markets Direct

Abstracts

Gliosarcoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma – Pipeline Review, H1 2020, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 16, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Phase 0 stages comprises 1, 1 and 2 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Gliosarcoma - Overview
Gliosarcoma - Therapeutics Development
Gliosarcoma - Therapeutics Assessment
Gliosarcoma - Companies Involved in Therapeutics Development
Gliosarcoma - Drug Profiles
Gliosarcoma - Dormant Projects
Gliosarcoma - Discontinued Products
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gliosarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Gliosarcoma - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Gliosarcoma - Pipeline by Agenus Inc, H1 2020
Gliosarcoma - Pipeline by Apexigen Inc, H1 2020
Gliosarcoma - Dormant Projects, H1 2020
Gliosarcoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gliosarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Adastra Pharmaceuticals Inc
Agenus Inc
Apexigen Inc
Arog Pharmaceuticals Inc
Bayer AG
Berg LLC
Bristol-Myers Squibb Co
CDG Therapeutics Inc
DNAtrix Inc
EpicentRx Inc
ERC Belgium SA
Gilead Sciences Inc
Ipsen SA
Lumos Pharma Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
Mustang Bio Inc
Northwest Biotherapeutics Inc
Novartis AG
Oncologie Inc
TheraBiologics Inc
Transtarget Inc